V ascular smooth muscle cells (SMCs) are highly specialized in contraction, thus regulating the vascular tone. In contrast to other muscle cells, however, SMCs can reversibly undergo quite drastic phenotypic changes in response to environmental signals. 1 Following vascular injury, for instance, the expression of contractile proteins in SMCs substantially declines and these cells adopt a "synthetic" phenotype. 2 The origin of cells expressing SMC-specific markers in neointimal lesions or atherosclerotic plaques is known to be heterogeneous. The long-standing paradigm that these SMClike cells migrate from the media into the intima on injury has been challenged on the grounds that it may not be the only explanation of their provenience. Namely, seminal work by Sata et al 3 has provided evidence that-at least partly and depending on the degree of injury-SMC-like cells in different forms of arterial plaque development are derived from the bone marrow (BM). The extent to which BM-derived SMCs (BM-SMCs) contribute to the cellularity of the lesions appears to be rather variable. 4 Whereas BM-SMCs are frequent in neointimal lesions after mechanical injury, primarily generating a SMC-type response, they were rarely found in diet-induced atherosclerotic plaques. 5 This difference was considered essential, because the functional relevance of BM-SMCs was attributed merely to their passive accumulation in the lesions.
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In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Yu et al confirm the paucity of BM-SMCs in advanced primary atherosclerotic plaques in a very sophisticated mouse model using smooth muscle myosin heavy chain promoter activity as a suitable marker indicative of highly differentiated SMCs. 6 However, the authors proceed beyond this point to elucidate whether a relatively limited number of SMCs can affect plaque growth. Surprisingly, inducing apoptosis in lesional BM-SMCs that have SM22 promoter activity substantially decreased plaque size, revealing a functional role of this cell type beyond their pure presence in the plaque. Thus, a notion of "less is more" may hold true in terms of their powerful and detrimental effects on the local pathogenesis.
Naturally, the million-dollar question that arises is how such a small number of BM-SMCs can promote plaque growth. Strikingly, Yu et al found that the apoptosis of BM-SMCs primarily reduced the lesional macrophage content, indicating a proinflammatory and immune-modulatory effect. Considering that proinflammatory cytokines, chemokines, and mitogens are strongly expressed by many cell types in atherosclerotic plaques, the mechanism by which BM-SMCs drive arterial inflammation would have to be specific and predominant to make a difference. Indeed, Yu et al report that in vitro BM-SMCs express relatively high amounts of interleukin-6 and monocyte chemoattractant protein-1/CCL2, which may be sufficient to increase macrophage migration (Figure) . However, additional studies (eg, using cell-specific deletions) are required to determine whether this ultimately explains the effect of BM-SMCs on plaque growth. Moreover, the findings of Yu et al points toward a divergent role of resident versus BM-SMCs, as apoptosis of all SM22-expressing SMCs increases atherogenesis and confers features of increased plaque vulnerability. 7, 8 Likewise, the apoptosis of resident vascular SMCs has been reported by the same group to generate an inflammatory response in a hyperlipidemic context. 9 This raises the question of whether the apoptosis of BM-SMCs in the SM22-DTR model per se might exert beneficial effects on plaque growth.
To delineate this issue, blocking the recruitment or homeostasis of BM-SMCs to atherosclerotic lesions by other means could be an instructive approach. After arterial injury and in transplant arteriosclerosis, increased expression of SDF-1/ CXCL12 induces the CXCR4-dependent recruitment of circulating BM-derived smooth muscle progenitor cells, which give rise to neointimal formation and express SMC markers, such as ␣-smooth muscle actin, SM22, and smooth muscle myosin heavy chain, at distinct stages of their differentiation. 10 -12 In contrast, however, chronic interference with the CXCL12/CXCR4 axis clearly promotes atherosclerosis through a mobilization and disturbed homeostasis of neutrophils. 13 Thus, to selectively inhibit the accumulation of BM-derived smooth muscle progenitor cells producing BM-SMCs in the plaque and study a crucial role of SDF-1/ CXCR4 in their recruitment and subsequent processes, a more smooth muscle progenitor cell-specific approach seems warranted. This could be achieved by cell-specific and inducible deletion of CXCR4, eg, under control of smooth muscle myosin heavy chain or SM22. This could also be applied to a cell-specific deletion of incriminated cytokine mediators, namely interleukin-6 or monocyte chemoattractant protein-1/CCL2, and should ultimately help to clarify the mechanisms of action engaged by BM-SMCs in plaque growth (Figure) .
